Cancer costs on an ‘unaffordable trajectory’
September 28, 2011Sales and Marketing Cancer, healthcare costs
The cost of cancer is rising too fast with new treatments giving uncertain benefits, according to a new study. A …
Roche’s Herceptin successor impresses at EMCC
September 27, 2011Research and Development Herceptin, Roche, TDM-1
Roche’s next-generation breast cancer drug T-DM1 has impressed at the European cancer congress after besting Herceptin in a new study. …
Boehringer to create biosimilars division
September 27, 2011Research and Development Boehringer, biosimilars
Boehringer Ingelheim is to tap into the growing interest in biosimilars with the creation of a division dedicated to that …
MTS Medication Technologies appoints Paul O’Hanlon
September 27, 2011Manufacturing and Production appointments, manufacturing and production
MTS Medication Technologies has appointed Paul O’Hanlon as managing director of its International Division. He has 27 years of experience …
Lonza signs regenerative medicine deal with Mesoblast
September 27, 2011Manufacturing and Production Lonza, Mesoblast, pharma manufacturing news
Lonza has entered into a strategic-level alliance with Mesoblast, a specialist in regenerative medicines, which could see the construction of …
SCM Pharma unveils formulation development business
September 27, 2011Manufacturing and Production SCM Pharma, phamra manufacturing news, pharma manufacturing news
UK contract manufacturer SCM Pharma has set up a formulation development business, thanks to a collaboration with the University of …
Pharma manufacturing news in brief
September 26, 2011Manufacturing and Production pharma manufacturing news
This week’s roundup includes contract manufacturing updates from CMC Biologics, West-Ward and Aenova, plus a Catalent deal in Japan and …
Bridgehead International appoints Marcus Deans
September 26, 2011Sales and Marketing appointment, sales and marketing
London-based consultants Bridgehead International have appointed Marcus Deans as principal consultant. He joins the firm, which specialises in market access, …
Xarelto poised for two new chronic indications
September 26, 2011Sales and Marketing Xarelto
Bayer HealthCare’s oral bloodthinner Xarelto has been recommended for approval in Europe for two new chronic indications. The Committee for …
Roche’s Avastin set for new ovarian cancer indication in Europe
September 26, 2011Sales and Marketing avastin, ovarian cancer
Roche’s Avastin has gained the backing of European regulatory advisors for a new indication in ovarian cancer. The European Medicines …
Safety concerns prompt Multaq restrictions
September 26, 2011Sales and Marketing Multaq
The European Medicines Agency has recommended Sanofi’s Multaq be restricted due to ongoing concerns about its safety profile. The drug …
Avastin faces greater scrutiny over eye disease use
September 23, 2011Sales and Marketing avastin, macular oedema
The use of Roche’s Avastin to treat eye disease has come under greater scrutiny after a series of infections in …
Carolin Prasmo returns to Aurora
September 23, 2011Medical Communications appointment, medical communications
Farringdon, UK-based comms agency Aurora has appointed Carolin Prasmo as senior account account manager. She was originally one of the …
Virgo Health Education expands scientific and client service teams
September 23, 2011Medical Communications appointment, medical communications
Virgo has expanded its Health Education business unit with the appointments of Jenny Szkolar and Vicky Cadman. Jenny (pictured) joins …
Boehringer censured over Pradaxa marketing
September 23, 2011Medical Communications ABPI Code of Practice, Boehringer
Boehringer Ingelheim has been heavily censured by the body which enforces the ABPI’s Code of Practice for the content of …
Roche cleared over rep conduct complaint
September 23, 2011Sales and Marketing ABPI Code of Practice, Roche
Roche has been cleared by Code regulator the PMCPA of any wrongdoing after an NHS employee complained about the promotion …
Value-based pricing won’t encourage innovation, says ABPI
September 23, 2011Sales and Marketing value-based pricing
The ABPI has come out against the government’s reforms of drug pricing in the UK, saying its plans need a …
NHS ‘wasted’ £625 million on modern insulin
September 23, 2011Sales and Marketing diabetes, insulin
The NHS has wasted £625 million on modern insulin products over the last decade, according to a new report in …
Healthcare 2025: what the future holds for pharma
September 22, 2011Manufacturing and Production, Research and Development, Sales and Marketing NHS reform, healthcare reform, healthcare spending, prescribing
We are in the middle of a huge upheaval where everything we know is being turned on its head. Welcome …
J&J’s hep C drug Incivo approved in Europe
September 22, 2011Sales and Marketing Incivek, Incivo, Victrelis
J&J’s potential blockbuster hepatitis C treatment Incivo has been approved in Europe. Incivo (telaprevir) was approved in combination with peginterferon …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
